-
Benzinga's Top Pre-Market NASDAQ Gainers (MOTR, CYOU, NVTL, AIXG)
Monday, October 25, 2010 - 8:24am | 128Motricity Inc (NASDAQ: MOTR) rose 8.75% to $19.01 in the pre-market session. MOTR is all set to report its Q3 results on November 2. Changyou.com Limited (NASDAQ: CYOU) added 4.32% to $33.80 in the pre-market session. CYOU reported upbeat Q3 results. Novatel Wireless Inc (NASDAQ: NVTL) moved up 4....
-
Benzinga's Top ETF Decliners (SOXS, VXX, DTO, GAZ)
Friday, October 22, 2010 - 6:56pm | 168Direxion Daily Semiconductor Bear 3X Shares (NYSE: SOXS) led the decliners among ETFs on Friday with a loss of 5.72%. In the space, NVIDIA Corporation (NASDAQ: NVDA) spiked 6.40%, and Novellus Systems, Inc. (NASDAQ: NVLS) jumped 2.56%. iPath S&P 500 VIX Short-Term Futures ETN (NYSE: VXX) lost...
-
Ultratech Receives Multi-System, Follow-On Laser Spike Anneal Order
Friday, October 22, 2010 - 8:33am | 47Ultratech, Inc. (Nasdaq: UTEK) today announced that a large foundry in Asia has placed a significant multi-system, follow-on order for its laser spike anneal (LSA) tools. Ultratech plans to begin delivery of the systems in the fourth quarter of 2010.
-
Ultratech Announces Third Quarter 2010 Results; EPS $.20
Friday, October 22, 2010 - 8:31am | 77Ultratech, Inc. (Nasdaq: UTEK) today announced unaudited results for the three-month and nine-month periods ended October 2, 2010. For the third quarter of fiscal 2010, Ultratech reported net sales of $37.9 million as compared to $24.9 million during the third quarter of fiscal 2009. Ultratech's...
-
Cymer Beats Estimates (CYMI)
Thursday, October 21, 2010 - 5:04pm | 144Cymer Inc. (NASDAQ: CYMI) reports Q3 earnings of $0.70 versus consensus of $0.63. Cymer Inc. reports revenues of $141.7 million versus consensus of $137.24 million. "We executed well during the quarter, delivering solid financial performance. Our Installed Base Products revenue continued to...
-
Cymer Reports Third Quarter 2010 Operating Results; EPS $.36
Thursday, October 21, 2010 - 4:26pm | 136Cymer, Inc. (Nasdaq: CYMI) today announced operating results for the third quarter ended September 30, 2010. For the third quarter of 2010: net income totaled $20,881,000 equal to $0.70 per share (diluted), compared to net income of $10,785,000, equal to $0.36 per share (diluted) in the third...
-
Lam Research Beats Estimates (LRCX)
Wednesday, October 20, 2010 - 4:45pm | 92Lam Research (NASDAQ: LRCX) released its fiscal Q1 earnings results after the closing bell on Wednesday. The company reported net income of $193.7 million or $1.55 per share compared to $16.8 million or $0.13 per share in the year ago period. On an adjusted basis, EPS was $1.52. This came in ahead...
-
Lam Research Reports Strong Quarter (LRCX)
Wednesday, October 20, 2010 - 4:36pm | 42Lam Research Corporation (NASDAQ: LRCX) reports Q3 earnings of $1.55 versus consensus of $1.37. Lam Research Corporation reports revenues of $805.9 million versus consensus of $794.41 million. Shares of LRCX closed at $41.25 today, a gain of 48 cents or 1.2%.
-
MKS Instruments Reports Q3 2010 Financial Results; EPS $.72
Wednesday, October 20, 2010 - 4:32pm | 161MKS Instruments, Inc. (Nasdaq: MKSI), a global provider of technologies that enable advanced processes and improve productivity, today reports third quarter 2010 financial results. Sales remained strong and were $221.3 million, up from $220.6 million in the second quarter of 2010, and an increase...
-
Cohu Reports Third Quarter 2010 Operating Results; EPS $.41
Wednesday, October 20, 2010 - 4:29pm | 79Cohu, Inc. (NASDAQ: COHU) today reported fiscal 2010 third quarter net sales of $86.1 million and GAAP net income of $7.6 million or $0.32 per share. Net sales for the first nine months of 2010 were $225.8 million and GAAP net income was $15.2 million or $0.63 per share. The Company also reported...
-
Benzinga's Top Pre-Market NASDAQ Losers (AMLN, ALKS, FSII, CREE)
Wednesday, October 20, 2010 - 9:33am | 147Amylin Pharmaceuticals Inc (NASDAQ: AMLN) dipped 47.63% to $10.73 in the pre-market session. The Food and Drug Administration has refused to give approval to AMLN's long-acting diabetes drug Bydureon. as FDA wants more testing on the drug. Alkermes Inc (NASDAQ: ALKS) lost 23.52% to $11.09 in the...
-
Benzinga's Top Pre-Market NASDAQ Losers (AMLN, ALKS, FSII, CREE)
Wednesday, October 20, 2010 - 9:24am | 147Amylin Pharmaceuticals Inc (NASDAQ: AMLN) dipped 47.63% to $10.73 in the pre-market session. The Food and Drug Administration has refused to give approval to AMLN's long-acting diabetes drug Bydureon. as FDA wants more testing on the drug. Alkermes Inc (NASDAQ: ALKS) lost 23.52% to $11.09 in the...
-
Benzinga's Top Pre-Market NASDAQ Losers (AMLN, ALKS, FSII, CREE)
Wednesday, October 20, 2010 - 9:08am | 147Amylin Pharmaceuticals Inc (NASDAQ: AMLN) dipped 47.63% to $10.73 in the pre-market session. The Food and Drug Administration has refused to give approval to AMLN's long-acting diabetes drug Bydureon. as FDA wants more testing on the drug. Alkermes Inc (NASDAQ: ALKS) lost 23.52% to $11.09 in the...
-
Benzinga's Top Pre-Market NASDAQ Losers (AMLN, ALKS, FSII, CREE)
Wednesday, October 20, 2010 - 9:00am | 147Amylin Pharmaceuticals Inc (NASDAQ: AMLN) dipped 47.63% to $10.73 in the pre-market session. The Food and Drug Administration has refused to give approval to AMLN's long-acting diabetes drug Bydureon. as FDA wants more testing on the drug. Alkermes Inc (NASDAQ: ALKS) lost 23.52% to $11.09 in the...
-
Deutsche Bank Downs WFR To Hold
Wednesday, October 20, 2010 - 6:47am | 52Analysts at Deutsche Bank downgrade MEMC Electronic Materials Inc (NYSE: WFR) from "buy" to "hold." The target price for WFR has been reduced from $18 to $15. WFR shares lost 2.62% to close at $12.66 yesterday. More Analyst Ratings here